Haemonetics Stock Price, Forecast & Analysis (NYSE:HAE)

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Haemonetics announced that its board has authorized a share repurchase program on Tuesday, February 6th 2018, which allows the company to repurchase $260,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Stock repurchase programs are typically an indication that the company's leadership believes its stock is undervalued.

Haemonetics Co. (NYSE:HAE) announced its quarterly earnings data on Tuesday, August, 7th. The medical instruments supplier reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.42 by $0.17. The medical instruments supplier earned $229.35 million during the quarter, compared to analyst estimates of $219.52 million. Haemonetics had a return on equity of 24.59% and a net margin of 6.90%. View Haemonetics' Earnings History.

Haemonetics is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Haemonetics.

Haemonetics issued an update on its FY20 earnings guidance on Friday, November, 1st. The company provided earnings per share guidance of $3.10-3.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.09. The company issued revenue guidance of +3-5% yr/yr to ~$996.6 million to $1.02 billion, compared to the consensus revenue estimate of $1.01 billion.

5 analysts have issued 12-month target prices for Haemonetics' stock. Their forecasts range from $140.00 to $150.00. On average, they anticipate Haemonetics' share price to reach $144.80 in the next twelve months. This suggests a possible upside of 21.0% from the stock's current price. View Analyst Price Targets for Haemonetics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Haemonetics.

News articles about HAE stock have trended somewhat negative recently, according to InfoTrie. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Haemonetics earned a coverage optimism score of -1.4 on InfoTrie's scale. They also assigned media coverage about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Haemonetics.

Haemonetics saw a decline in short interest in October. As of October 31st, there was short interest totalling 717,000 shares, a decline of 13.3% from the September 30th total of 826,800 shares. Based on an average daily volume of 337,600 shares, the days-to-cover ratio is currently 2.1 days. Approximately 1.4% of the shares of the stock are sold short. View Haemonetics' Current Options Chain.

Some companies that are related to Haemonetics include Align Technology (ALGN), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), West Pharmaceutical Services (WST), ICU Medical (ICUI), Neogen (NEOG), Quidel (QDEL), STAAR Surgical (STAA), Merit Medical Systems (MMSI), Atrion (ATRI), Anika Therapeutics (ANIK), Antares Pharma (ATRS), Cerus (CERS), OraSure Technologies (OSUR) and Utah Medical Products (UTMD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include Endologix (ELGX), Align Technology (ALGN), Micron Technology (MU), Apache (APA), Chipotle Mexican Grill (CMG), Zoetis (ZTS), NVIDIA (NVDA), Adobe (ADBE), Aegean Marine Petroleum Network (ANW) and Citigroup (C).

Haemonetics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Eagle Asset Management Inc. (1.17%), Fisher Asset Management LLC (0.47%), Russell Investments Group Ltd. (0.45%), Emerald Advisers LLC (0.40%), Emerald Mutual Fund Advisers Trust (0.35%) and Rhumbline Advisers (0.31%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Mark W Kroll, Michelle L Basil, Neil Mr Ryding, Pedro P Granadillo, Richard J Meelia, Ronald G Gelbman, Said Bolorforosh, Willaim P Burke and William P Mr Burke. View Institutional Ownership Trends for Haemonetics.

HAE stock was sold by a variety of institutional investors in the last quarter, including Picton Mahoney Asset Management, Morse Asset Management Inc, Rhumbline Advisers, Systematic Financial Management LP, Baldwin Brothers Inc. MA, New York State Teachers Retirement System, Russell Investments Group Ltd. and Pacer Advisors Inc.. Company insiders that have sold Haemonetics company stock in the last year include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Michelle L Basil, Richard J Meelia, Ronald G Gelbman, Said Bolorforosh and William P Mr Burke. View Insider Buying and Selling for Haemonetics.

HAE stock was acquired by a variety of institutional investors in the last quarter, including Cookson Peirce & Co. Inc., Public Employees Retirement Association of Colorado, Lisanti Capital Growth LLC, State of New Jersey Common Pension Fund D, California Public Employees Retirement System, First Trust Advisors LP, Catalyst Capital Advisors LLC and Mackay Shields LLC. View Insider Buying and Selling for Haemonetics.

Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HAE stock can currently be purchased for approximately $119.64.

Haemonetics has a market capitalization of $6.06 billion and generates $967.58 million in revenue each year. The medical instruments supplier earns $55.02 million in net income (profit) each year or $2.39 on an earnings per share basis. Haemonetics employs 3,216 workers across the globe.View Additional Information About Haemonetics.

The official website for Haemonetics is http://www.haemonetics.com/.

Haemonetics' mailing address is 400 WOOD RD, BRAINTREE MA, 02184. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]